6, on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41042/ abstract Three trials of methotrexate with negative results tested doses of â‰¤10 mg weekly, and the lack of benefit may reflect the low doses used A phase II study of tofacitinib showed benefit in both clinical and imaging outcomes of axial disease over 12 weeks http://onlin e libr ary.wiley.com/doi/10.1002/art.41042/ abstract In adults with active AS despite treatment with NSAIDs, we strongly recommend treatment with TNFi over no treatment with TNFi (PICO 6). In adults with active AS despite treatment with NSAIDs, we do not recommend any particular TNFi as the preferred choice (PICO 5). The efficacy of TNFi in patients with active AS has been demonstrated in 24 randomized controlled trials, most of which were short-term (6 months or shorter) placebo-controlled studies. Improvements were shown in patient-reported outcomes, composite response criteria, and spine and sacroiliac